Top 10 Biotechnology Stocks to Watch in Nov 2024: Essential Guide for Investors
Nov 21, 2024 03:15What are Biotechnology Stocks?
The biotech sector is a rapidly evolving field that involves the use of biological systems and organisms to develop new products and technologies. This sector encompasses several subfields including pharmaceuticals, agricultural biotechnology, and industrial biotechnology, all of which have significant impacts on human health and the environment. Biotech companies typically focus on developing innovative treatments, improving crop cultivation techniques, and creating sustainable bioengineering solutions.
Key Aspects of Biotech Stocks
Pharmaceutical Biotechnology:
- Companies focused on developing new drugs and treatment methods.
- Examples: Amgen, Biogen and Gilead Sciences.
Agricultural Biotechnology:
- Companies using biotechnology to improve crop cultivation and increase agricultural yields.
- Examples: Monsanto, Syngenta and Corteva.
Industrial Biotechnology:
- Companies developing biotechnological solutions for environmental and production processes.
- Examples: Novozymes, Danisco and BASF.
10 Top Biotechnology Stocks
Vertex Pharmaceuticals(VRTX.US)
Company overview
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Market value of Vertex Pharmaceuticals(VRTX.US): US$114.992B
Stock price performance in 2024: +9.74%
What's the latest news:
Healthcare Conference: Vertex Pharmaceuticals presented at the Stifel 2024 Healthcare Conference.
Price Target Raised: Citi maintains a Buy rating on Vertex Pharmaceuticals, raising the target price from $541 to $575.
Options Market Analysis: The options market shows a significant bearish stance on Vertex Pharmaceuticals.
Innovation Conference: Vertex Pharmaceuticals discussed at the Guggenheim Inaugural Healthcare Innovation Conference.
Citi Initiates Coverage: Citi initiated coverage of Vertex Pharmaceuticals with a Buy rating and a price target of $575.
Regeneron Pharmaceuticals(REGN.US)
Company overview
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Market value of Regeneron Pharmaceuticals(REGN.US): US$81.351B
Stock price performance in 2024: -15.71%
What's the latest news:
Whales Buy REGN: Large investors take a bullish stance on Regeneron Pharmaceuticals.
28 Analysts Rate REGN: 28 analysts offer diverse ratings for Regeneron Pharmaceuticals.
REGN at Jefferies Conference: Regeneron Pharmaceuticals participates in the 2024 Jefferies London Healthcare Conference.
REGN Short Interest Rises: Short interest in Regeneron Pharmaceuticals increases to 1.78%.
Citi Upgrades REGN: Citi analyst upgrades Regeneron Pharmaceuticals to hold, raises target price to $895.
argenx SE(ARGX.US)
Company overview
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Market value of argenx SE(ARGX.US): US$34.847B
Stock price performance in 2024: +53.18%
What's the latest news:
Drug Development Continues: argenx to continue developing its autoimmune disease drug, efgartigimod.
Collaboration with Steritas: argenx announces collaboration with Steritas to advance evidence for steroid-sparing therapeutics.
Morgan Stanley Maintains Buy: Morgan Stanley raises argenx's target price from $580 to $675.
Stifel Maintains Buy Rating: Stifel analyst maintains argenx's target price at $707.
JMP Securities Maintains Buy: JMP Securities maintains argenx's target price at $606.
Alnylam Pharmaceuticals(ALNY.US)
Company overview
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Market value of Alnylam Pharmaceuticals(ALNY.US): US$31.554B
Stock price performance in 2024: +27.81%
What's the latest news:
Buy Rating Reaffirmed: TD Cowen analyst Ritu Baral reaffirms a Buy rating for Alnylam Pharmaceuticals with a target price of $371.
Target Price $371: TD Cowen analyst Ritu Baral maintains a Buy rating and a target price of $371 for Alnylam Pharmaceuticals.
Target Price $296: Piper Sandler maintains a target price of $296 for Alnylam Pharmaceuticals.
Phase 1 Data on Nucresiran: Alnylam Pharmaceuticals announces promising Phase 1 study results for its drug Nucresiran, showing significant efficacy.
Maintains $400 Target Price: H.C. Wainwright analyst Patrick Trucchio maintains a Buy rating and a target price of $400 for Alnylam Pharmaceuticals.
BioNTech(BNTX.US)
Company overview
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Market value of BioNTech(BNTX.US): US$24.427B
Stock price performance in 2024: -3.46%
What's the latest news:
Stock up 1.9%: BioNTech shares rose 1.9% after Evercore ISI upgraded the stock to outperform.
Goldman maintains buy: Goldman Sachs analyst maintains a buy rating on BioNTech with a target price of $137.
Analysts turn bullish: Amid market volatility, analysts upgraded BioNTech to outperform with a new target price of $125.
Director plans stock sale: BioNTech director Jeggle Helmut Wolfgang plans to sell 150,000 shares valued at approximately $15.534 million.
J.P. Morgan holds: J.P. Morgan analyst maintains a hold rating on BioNTech with a target price of $124.
BeiGene(BGNE.US)
Company overview
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Market value of BeiGene(BGNE.US): US$20.589B
Stock price performance in 2024: +7.45%
What's the latest news:
Maintains Buy Rating: Dongwu Securities reports strong Q3 sales and cash flow for BeiGene, maintains buy rating.
Target Price Adjusted: Morgan Stanley adjusts BeiGene's target price from HK$126.2 to HK$125 and maintains a neutral rating.
New CFO Appointed: Labcorp Holdings appoints Julia Wang as the new Chief Financial Officer, effective December 2.
Target Price Increased: Bank of Communications International raises BeiGene's target price to HK$159, optimistic about Q3 sales and operations.
Target Price Raised: BofA Securities maintains a hold rating on BeiGene and raises the target price from $198 to $207.
United Therapeutics(UTHR.US)
Company overview
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Market value of United Therapeutics(UTHR.US): US$16.176B
Stock price performance in 2024: +64.78%
What's the latest news:
Executive Stock Sale: United Therapeutics executive Michael Benkowitz plans to sell 40,000 shares valued at $14.53 million.
Officer Sells Shares: United Therapeutics officer Michael Benkowitz sold 10,000 shares for a total of $3.59 million.
Moderna(MRNA.US)
Company overview
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Market value of Moderna(MRNA.US): US$14.059B
Stock price performance in 2024: -63.26%
What's the latest news:
Analyst Ratings Update: Several analysts have updated their ratings and price targets for Moderna.
Piper Sandler Lowers Target: Piper Sandler reiterates an Overweight rating on Moderna but lowers the price target from $115 to $69.
RFK Jr's Appointment Impacts Stock: Moderna's stock price plummeted after RFK Jr was appointed to head the U.S. Department of Health and Human Services, presenting an attractive entry point according to Piper Sandler.
Baptista Upgrades Moderna: Baptista upgrades Moderna to Buy with a price target set at $48, noting an average hold rating and mean price target of $75.15 from analysts.
Summit Therapeutics(SMMT.US)
Company overview
Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
Market value of Summit Therapeutics(SMMT.US): US$13.761B
Stock price performance in 2024: +614.94%
What's the latest news:
Maintains Buy Rating: H.C. Wainwright analyst Mitchell Kapoor maintains a buy rating for Summit Therapeutics with a target price of $44.
Quarterly Loss: Bronte Capital's Amalthea Fund reported a 3.72% loss in Q3, mentioning Summit Therapeutics' performance.
Strategic Position Strengthens Buy: Analyst Mitchell Kapoor reiterates a buy rating for Summit Therapeutics due to its strategic position in the oncology pharmaceutical market.
Reiterates Buy Rating: HC Wainwright & Co. analyst Mitchell Kapoor reiterates a buy rating for Summit Therapeutics, maintaining a $44 price target.
Incyte(INCY.US)
Company overview
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Market value of Incyte(INCY.US): US$13.615B
Stock price performance in 2024: +12.55%
What's the latest news:
CSU Study Paused: Incyte shares drop 13% after pausing CSU study and ending pruritus treatment.
Escient Deal Setback: Incyte's $750 million deal with Escient faces challenges due to toxicology issues.
Neutral Rating Reiterated: Cantor Fitzgerald reiterates a neutral rating on Incyte.
Analyst Ratings Summary: Recent analyst ratings show mixed views on Incyte.
Understanding Analyst Reviews: 16 analysts share diverse opinions and expectations on Incyte.
To start trading stocks, the initial step is to acquire a brokerage account. When choosing an online stock brokerage, there are two critical factors to consider: brokerage offerings and a user-friendly platform. Futubull app would be helpful.
Step 2: Deciding how many shares to buy
To gain initial experience, it's wise to paper trade using a stock market simulator. Alternatively, start with a small investment amount.
Step 3: Buying stocks using the right order type
To master stock buying, it's essential to understand three critical order types: market orders, limit orders, and stop orders.
Step 4: Placing the stock order with your brokerage
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty. Read More
